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Background
Poor neurodevelopmental outcomes and recurrences of cutaneous lesions remain unac-
ceptably frequent among survivors of neonatal herpes simplex virus (HSV) disease.
Methods
We enrolled neonates with HSV disease in two parallel, identical, double-blind, pla-
cebo-controlled studies. Neonates with central nervous system (CNS) involvement were 
enrolled in one study, and neonates with skin, eye, and mouth involvement only were 
enrolled in the other. After completing a regimen of 14 to 21 days of parenteral acy-
clovir, the infants were randomly assigned to immediate acyclovir suppression (300 mg 
per square meter of body-surface area per dose orally, three times daily for 6 months) 
or placebo. Cutaneous recurrences were treated with open-label episodic therapy.
Results
A total of 74 neonates were enrolled — 45 with CNS involvement and 29 with skin, 
eye, and mouth disease. The Mental Development Index of the Bayley Scales of In-
fant Development (in which scores range from 50 to 150, with a mean of 100 and 
with higher scores indicating better neurodevelopmental outcomes) was assessed in 
28 of the 45 infants with CNS involvement (62%) at 12 months of age. After adjust-
ment for covariates, infants with CNS involvement who had been randomly assigned 
to acyclovir suppression had significantly higher mean Bayley mental-development 
scores at 12 months than did infants randomly assigned to placebo (88.24 vs. 68.12, 
P = 0.046). Overall, there was a trend toward more neutropenia in the acyclovir 
group than in the placebo group (P = 0.09).
Conclusions
Infants surviving neonatal HSV disease with CNS involvement had improved neu-
rodevelopmental outcomes when they received suppressive therapy with oral acy-
clovir for 6 months. (Funded by the National Institute of Allergy and Infectious 
Diseases; CASG 103 and CASG 104 ClinicalTrials.gov numbers, NCT00031460 and 
NCT00031447, respectively.)
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The outcomes of neonatal herpes simplex virus (HSV) disease are dependent on the extent of the disease.1 Approximately 
30% of babies with disseminated disease die, but 
only 20% of survivors have neurologic sequelae.2 
In contrast, only 6% of babies with central nervous 
system (CNS) disease die, but approximately 70% 
have permanent neurologic impairment.2 Skin, eye, 
and mouth disease is not associated with death, 
and neurologic impairment is rare with this man-
ifestation of neonatal herpes.3
HSV establishes latency in sensory ganglia, 
with periodic reactivation and recurrence of local-
ized disease.4,5 Whether the virus subclinically re-
activates in the brain after neonatal HSV disease 
is not known. If reactivation in the brain does oc-
cur, it could contribute to the serious neurologic 
sequelae associated with neonatal HSV disease 
with CNS involvement, as has been suggested.6
Antiviral suppressive therapy prevents the re-
currence of localized disease in persons with 
genital7-10 or orolabial11,12 HSV infection. The Na-
tional Institute of Allergy and Infectious Diseases 
(NIAID) Collaborative Antiviral Study Group 
(CASG) conducted parallel, identical, phase 3, 
placebo-controlled studies of oral acyclovir sup-
pressive therapy after neonatal HSV disease to 
determine the efficacy and safety of long-term 
antiviral administration during infancy.
Me thods
Study Design and Oversight
From August 1997 through April 2008, we en-
rolled infants with HSV disease in two trials: in-
fants with CNS involvement (stratified according 
to CNS disease alone or disseminated disease with 
CNS involvement) were enrolled in the CASG 103 
trial, and infants with skin, eye, and mouth dis-
ease only were enrolled in the CASG 104 trial. The 
institutional review board at each participating in-
stitution approved the studies. The protocols, in-
cluding the statistical analysis plans, are available 
with the full text of this article at NEJM.org. All 
authors vouch for the completeness and accuracy 
of the data presented, as well as the fidelity of the 
studies to the protocols. The NIAID convened a 
data and safety monitoring board, which oversaw 
the studies. Oral acyclovir and matching placebo 
were supplied by GlaxoSmithKline, Alpharma 
USPD, and Pharm Ops. None of these companies 
had any role in the design or conduct of the trials, 
the collection or analysis of the data, the prepa-
ration of the manuscript, or the decision to submit 
the manuscript for publication. Written informed 
consent was obtained from a parent or guardian of 
each study subject before study activities proceeded.
Study Population
Inclusion criteria for both studies were HSV infec-
tion, as confirmed by culture or, in the case of in-
fants in the CASG 103 study who did not have skin 
lesions, detection of HSV DNA in cerebrospinal 
fluid by polymerase-chain-reaction (PCR) assay; 
disease onset within the first 28 days of age; and 
a body weight of at least 800 g at the time of en-
rollment. Infants in the CASG 103 study had to 
have documentation of abnormal cerebrospinal 
fluid indexes or abnormal findings on neuroim-
aging studies or electroencephalograms or had to 
have cerebrospinal fluid that was positive for HSV 
DNA, as detected by PCR assay, whereas subjects 
in the CASG 104 study had normal results. In or-
der for infants in the CASG 103 study to be eligible 
to undergo randomization after the initial regimen 
of parenteral acyclovir, they had to have cerebro-
spinal f luid that was negative for HSV DNA, as 
detected by PCR assay, after completion of that 
regimen.
The primary end point of both studies was 
neurodevelopmental status at 12 months of age, 
as assessed with the use of the Bayley Scales of 
Infant Development, second edition. Secondary 
end points were two or fewer recurrences of cu-
taneous lesions during the first 12 months of age 
and detection by PCR assay of HSV DNA in the 
cerebrospinal f luid during or after suppressive 
therapy. The tertiary end point was toxic effects 
of grade 2 or higher, as assessed with the use of 
the World Health Organization (WHO) Toxicity 
Grading Scale.13
All the infants completed a 14-day course (in 
the case of the infants with skin, eye, and mouth 
disease) or a 21-day course (in the case of infants 
with CNS involvement) of parenteral acyclovir, as 
is the standard of care.14 Infants in both studies 
were then randomly assigned, in a 1:1 ratio, to oral 
acyclovir or placebo, in a double-blind fashion. The 
study drug was administered at a dose of 300 mg 
per square meter of body-surface area, adminis-
tered three times daily for 6 months.15 Per proto-
col, after an infant had a second cutaneous recur-
rence (i.e., exceeded the secondary end point), the 
randomly assigned oral acyclovir or placebo was 
discontinued, and open-label oral acyclovir sup-
pression was allowed.
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Clinical and Safety Assessments
Assessments were performed at 2 weeks and 
4 weeks after the first administration of the study 
drug and then monthly throughout the 6-month 
period during which the infants received suppres-
sive treatment with the study drug or an open-
label drug. The infants were then seen at 1 year 
of age for an assessment of end points. The neu-
rodevelopmental pediatricians and psychologists 
performing the Bayley Scales of Infant Develop-
ment testing were not aware of the treatment as-
signments. Laboratory testing to assess safety was 
performed at each visit during the period in which 
the infants were receiving suppressive treatment.
Statistical Analysis
Demographic and baseline clinical characteristics 
and results of the grading of laboratory-test ab-
normalities after intravenous acyclovir therapy 
were compared with the use of the Kruskal–Wal-
lis test for continuous variables and Fisher’s exact 
test for categorical variables. For the primary ef-
ficacy analyses, a two-sample t-test was used to 
determine whether assignment to suppressive ther-
apy with oral acyclovir was associated with signifi-
cantly improved neurodevelopmental outcomes at 
12 months of age. An analysis-of-covariance model 
was also used to adjust for baseline clinical fac-
tors that were unbalanced between the two treat-
ment groups (P≤0.10). A Kaplan–Meier analysis 
with a log-rank test was used to determine wheth-
er suppressive therapy with oral acyclovir reduced 
the time to the second recurrence of skin lesions 
and whether it prevented the appearance of HSV 
DNA in the cerebrospinal fluid, as assessed by 
PCR, during the 12-month period after comple-
tion of intravenous acyclovir therapy. Fisher’s ex-
act test was used to compare toxic effects between 
the two groups. A repeated-measures analysis was 
used to compare the two groups with respect to 
abnormalities in laboratory-test results during the 
period from baseline to month 6.
R esult s
Demographic and Baseline Characteristics  
of the Subjects
A total of 45 infants underwent randomization at 
19 institutions as part of the CASG 103 study — 
37 with CNS disease and 8 with disseminated dis-
ease and CNS involvement; 29 infants with skin, 
eye, and mouth disease underwent randomization 
at 12 institutions as part of the CASG 104 study. 
As shown in Table 1, the two groups in each study 
were balanced with respect to the extent of neu-
rologic involvement, viral type, and gestational age. 
Infants with CNS disease who were randomly 
assigned to acyclovir, as compared with those 
assigned to placebo, had a lower median birth 
weight (P = 0.01), median weight at study enroll-
ment (P = 0.01), and median head circumference 
at birth (P = 0.03). Infants with skin, eye, and mouth 
disease who were randomly assigned to acyclovir, 
as compared with those assigned to placebo, 
had lower median weight at enrollment (P = 0.03) 
(Table 1 in the Supplementary Appendix, available 
at NEJM.org).
Of the 45 infants in the CASG 103 (CNS) study, 
39 (87%) either completed 6 months of therapy 
(23 subjects) or had two recurrences of cutaneous 
lesions (16); the other 6 infants did not complete 
the full 6 months of therapy for the following rea-
sons: loss to follow-up (1 infant), nonadherence to 
the protocol (2), withdrawn consent (2), and death 
(1 in the placebo group) (Fig. 1A). The baseline 
characteristics of the 6 infants who did not com-
plete 6 months of treatment did not differ sig-
nificantly from those of the infants who did.
Of the 29 infants in the CASG 104 (skin, eye, 
and mouth disease) study, 26 (90%) either com-
pleted 6 months of therapy (12) or reached the 
study end point after two cutaneous recurrences 
(14); the other 3 infants did not complete the full 
6 months of therapy because of loss to follow-up 
(1) and nonadherence to the protocol (2) (Fig. 1B). 
The baseline characteristics of the 3 infants who 
did not complete 6 months of treatment did not 
differ significantly from those of the infants 
who did.
Cutaneous Recurrences
The likelihood of skin recurrences after neonatal 
HSV disease is not affected by disease classifica-
tion.3 In an analysis that included data from the 
74 infants in the two studies combined and that 
evaluated the time to discontinuation of the study 
medication because the infant had two cutaneous 
recurrences, the median time the infants received 
the study drug was 2.5 months longer among in-
fants assigned to acyclovir than among those as-
signed to placebo (P = 0.009) (Fig. 2C). In the CASG 
103 (CNS) study, the median time the infants re-
ceived the study drug was 4.1 months longer 
among infants assigned to acyclovir than to those 
assigned to placebo (P = 0.04) (Fig. 2A). In the CASG 
104 (skin, eye, and mouth disease) study, the me-
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dian time the infants received the study drug was 
1.7 months longer among infants assigned to acy-
clovir than to those assigned to placebo (P = 0.24) 
(Fig. 2B). In a regression analysis of the two thirds 
of infants for whom the viral type was known 
(Table 1), the likelihood of cutaneous recurrenc-
es was not affected by viral type.
Recurrences of CNS Disease
Three infants in the CASG 103 study had a recur-
rence of CNS disease during the 12 months after 
enrollment in the study. Two had been assigned 
to placebo (both term babies), and one had been 
assigned to acyclovir (a 28-week premature infant) 
(P = 0.59). All three had cerebrospinal fluid that 
was positive for HSV DNA, as detected by PCR 
assay, at the time of the recurrence of CNS dis-
ease and had an adequate therapeutic and viro-
logic response to another course of parenteral acy-
clovir, suggesting that acyclovir resistance was 
unlikely. During the same period, no infant in the 
CASG 104 study had a recognized occurrence of 
CNS disease.
Neurodevelopmental Outcomes
A total of 28 of the 45 infants (62%) enrolled in 
the CASG 103 (CNS) study had a Bayley Scales of 
Infant Development assessment at 12 months (Fig. 
1A). Baseline demographic and clinical charac-
teristics, including assessments of the extent of 
neurologic involvement, were similar between the 
28 subjects who had a Bayley Scales of Infant De-
velopment assessment at 12 months of age and 
the 17 who did not (Table 2, and Table 2 in the 
Supplementary Appendix). For subjects with CNS 
disease, an analysis-of-covariance model was used 
to adjust for the covariates at baseline that were 
unbalanced between the groups. The covariates 
that were examined included age at enrollment, 
birth weight, weight at enrollment, head circum-
ference at birth, head circumference at enrollment, 
Apgar scores at 1 and 5 minutes, gestational age, 
the presence of cutaneous lesions during the ini-
tial illness, and viral type (HSV-1 or HSV-2). After 
adjustment for covariates that had P values of 
0.10 or less (head circumference at birth, birth 
weight, and enrollment weight), infants assigned 
Table 1. Baseline Demographic and Clinical Characteristics, According to Study-Drug Assignment.*
Characteristic CASG 103 CASG 104
CNS Disease
Disseminated Disease  













Gestational age — wk
Median 37 38 40 39 38 39
Range 25–41 35–40 40–41 38–40 27–40 27–41
HSV type — no./total no. (%)†
I 2/14 (14) 3/11 (27) 1/2 (50) 1/3 (33) 5/12 (42) 5/11 (45)
II 12/14 (86) 8/11 (73) 1/2 (50) 2/3 (67) 7/12 (58) 6/11 (55)
White-cell count in cerebrospinal fluid at presentation 
— cells/mm3
Median 91.5 109.0 3.0 2.0 4.0 6.0
Range 10–1216 5–58,080 1–18 0–13 0–20 0–33
HSV DNA in cerebrospinal fluid at presentation — 
no./total no. (%)‡
Positive 17/21 (81) 12/16 (75) 2/3 (67) 3/5 (60) 0 0
Negative 4/21 (19) 4/16 (25) 1/3 (33) 2/5 (40) 14/14 (100) 13/13 (100)
Evidence of HSV disease on MRI — no./total no. (%) 10/16 (62) 9/14 (64) 1/3 (33) 0 0 0
Abnormal EEG — no./total no. (%) 9/13 (69) 10/14 (71) 1/1 (100) 0 NA NA
* None of the characteristics differed significantly between the groups (P>0.05 for all comparisons). EEG denotes electroencephalogram, HSV 
herpes simplex virus, MRI magnetic resonance imaging, and NA not applicable.
† The viral type was unknown in the case of some infants.
‡ HSV DNA in cerebrospinal fluid was detected with the use of a polymerase-chain-reaction assay.
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to receive acyclovir had significantly higher mean 
Bayley mental-development scores at 1 year (88.24 
vs. 68.12, P = 0.046). Among subjects in the CASG 
103 (CNS) study assigned to suppressive therapy 
with oral acyclovir, 69% had normal neurologic 
outcomes, 6% had mild impairment, 6% had mod-
erate impairment, and 19% had severe impairment; 
the corresponding proportions among subjects 
assigned to placebo were 33%, 8%, 25%, and 33%. 
Among subjects in the CASG 104 (skin, eye, and 
mouth) study, no significant differences in Bayley 
mental-development scores were noted. In a regres-
sion analysis of data from the two thirds of subjects 
for whom the viral type was known (Table 1), 
neurodevelopmental outcomes did not differ sig-
nificantly according to viral type in either study.
A total of 15 infants in the CASG 103 (CNS) 
study received suppressive therapy with oral acy-
clovir for the entire 6-month study-drug period 
(Fig. 1A, yellow boxes), whereas 6 infants received 
acyclovir suppression for part of the 6-month treat-
ment period (Fig. 1A, light blue boxes) and 7 sub-
jects received no active suppression throughout 
the study (Fig. 1A, pink boxes). The 12-month Bay-
ley mental-development scores were incremen-
tally higher as infants were receiving acyclovir 
suppression for longer periods of time: among in-
fants receiving suppressive therapy for 6 months, 
the mean (±SE) scores were 85±5 (median, 91); 
among infants receiving suppressive therapy for 
less than 6 months, the mean scores were 80±8 
(median, 70); and among infants receiving no 
suppressive therapy, the mean scores were 73±10 
(median, 58). Bayley motor-development scores did 
not differ significantly between the groups in ei-
ther study.
Safety Assessments
There was no significant difference in absolute 
neutrophil counts between the infants receiving 
oral acyclovir and those receiving placebo in ei-
ther study (Table 3). The time to the first abso-
lute neutrophil count of 500 cells per cubic mil-
limeter or less in the combined studies did not 
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Figure 2. Time to Discontinuation of Study Drug.
Per protocol, the study drug was discontinued if an 
 infant had two cutaneous recurrences. The time to 
 discontinuation of the study drug is shown among 
 subjects in the CASG 103 study (Panel A), which in-
cluded neonates with HSV disease with central ner-
vous system (CNS) involvement, among subjects in 
the CASG 104 study (Panel B), which included neo-
nates with HSV disease with skin, eye, and mouth 
 involvement only, and among the subjects in the two 
groups combined (Panel C).
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to acyclovir and those assigned to placebo, al-
though a trend for neutropenia was noted among 
those who received acyclovir (P = 0.09). In total, 
an absolute neutrophil count of 500 cells per cu-
bic millimeter or less developed in 25% of the 
subjects in the CASG 103 (CNS) study and in 20% 
of those in the CASG 104 (skin, eye, and mouth) 
study who were assigned to acyclovir, as compared 
with 5% and 7%, respectively, of those who were 
assigned to placebo. Neutropenia resolved in all 
the affected infants, in some cases with and in 
other cases without cessation of suppressive ther-
apy, and none had associated complications.
No significant differences between the groups 
were seen with respect to other hematologic or 
chemical laboratory tests or with respect to ad-
verse events or serious adverse events (Table 3 in 
the Supplementary Appendix). There were no ad-
verse events that led to discontinuation of the 
study drug.
Discussion
Therapeutic studies of rare diseases such as neo-
natal herpes present unique challenges. Each of 
the previous major investigations of the manage-
ment of neonatal HSV conducted by the CASG has 
spanned the course of a decade.2,3,16,17 The cur-
rent studies were no exception, requiring 11 years 
to enroll 74 infants. Many clinicians assumed that 
oral acyclovir would be efficacious, on the basis 
of the results of small, uncontrolled studies,18,19 
further challenging the conduct of these random-
ized, controlled trials. The long-term follow-up 
required to assess neurodevelopmental outcomes 
also affected the ability to follow all the enrolled 
infants for the primary protocol end point, with 
only 43 of the 74 infants (58%) having a Bayley 
Scales of Infant Development assessment at 12 
months (Fig. 1A and 1B).
Interpretation of the results of the neurode-
Table 2. Demographic and Clinical Characteristics of Infants with and without 12-Month Bayley Scales of Infant Development 
Assessments.*




No Bayley  
Assessment  




No Bayley  
Assessment  
(N = 14) P Value
Gestational age — wk 0.17 0.69
Median 39.5 38 38 39
Range 28–41 25–40 27–41 27–40
HSV type — no./total no. (%)† 0.03 0.003
I  7/19 (37) 0/11  2/13 (15) 8/10 (80)
II 12/19 (63) 11/11 (100) 11/13 (85) 2/10 (20)
White-cell count in cerebrospinal fluid at 
presentation — cells/mm3
0.98 0.48
Median 65 71 6 5
Range 1–58,080 0–1216 0–20 2–33
HSV DNA in cerebrospinal fluid at pre-
sentation — no./total no. (%)‡
0.16 0.22
Positive 19/28 (68) 15/17 (88) 0/15 0/12
Negative  9/28 (32)  2/17 (12) 15/15 (100) 12/12 (100)
Evidence of HSV disease on MRI — no./
total no. (%)
13/23 (57)  7/13 (54) 1.00 0 0 —
Abnormal EEG — no./total no. (%) 14/19 (74)  6/12 (50) 0.26 NA NA
* EEG denotes electroencephalogram, HSV herpes simplex virus, MRI magnetic resonance imaging, and NA not applicable.
† The viral type was unknown in the case of some infants.
‡ HSV DNA in cerebrospinal fluid was detected with the use of a polymerase-chain-reaction assay.
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velopmental assessment should be tempered by 
the fact that Bayley Scales of Infant Development 
assessments were not performed in 38% of sub-
jects in the CASG 103 (CNS) study. This substan-
tial attrition renders the primary protocol end 
point less interpretable. For the 62% of infants in 
the CASG 103 study with a neurologic evaluation 
at 12 months, our finding of improved neurode-
velopmental outcomes among subjects who start-
ed oral acyclovir suppression at the end of the 
21-day course of intravenous therapy provides the 
first controlled data that suggest that ongoing 
neurologic injury occurs in infants who survive 
neonatal HSV disease and that it can be decreased 
by longer-term antiviral suppression. This finding 
had previously been implied in small, uncontrolled 
case series.6,19
The distribution of neurologic outcomes among 
infants in the CASG 103 (CNS) study who were 
randomly assigned to placebo (normal, 33%; mild 
impairment, 8%; moderate impairment, 25%; se-
vere impairment, 33%) was similar to that among 
infants in an earlier trial (in whom the neurologic 
outcomes were measured by a different tool) who 
received high-dose parenteral acyclovir for the 
treatment of acute disease but no subsequent sup-
pression (normal, 31%; mild impairment, 15%; 
moderate impairment, 15%; severe impairment, 
39%).2 Similarly, the distribution of outcomes 
among infants in the CASG 103 (CNS) study who 
were randomly assigned to oral acyclovir was virtu-
ally identical to that from a small, uncontrolled 
case series (involving 16 infants) of oral acyclovir 
suppression after neonatal HSV CNS disease (69% 
with normal outcomes in both studies).19 The 
finding of incrementally higher neurodevelopmen-
tal scores among infants treated with oral anti-
viral suppressive therapy for the full 6 months as 
compared with those treated for only part of the 
6 months and as compared with those who re-
ceived no antiviral suppression (median 12-month 
Bayley mental-development score of 91 vs. 70 and 
58, respectively) also supports the conclusion that 
oral acyclovir suppressive therapy after treatment 
of acute neonatal HSV disease confers a benefit. 
If the infants who were randomly assigned to 
placebo had not been allowed to switch to active 
suppression after two cutaneous recurrences, it is 
possible that the difference between the acyclovir 
and placebo groups would have been more pro-
nounced. In addition, the subjects with CNS dis-
ease who were randomly assigned to acyclovir were 
smaller in size than were those assigned to pla-
cebo, as reflected in the lower birth weights and 
smaller head circumferences. However, any bias 
introduced by this difference should be in favor 
of the null hypothesis, since prematurity or small-
for-gestational-age status would be more likely to 
be associated with worse developmental outcomes.
Not surprisingly,7-12 these studies provided evi-
dence that suppressive therapy with oral acyclo-
vir decreases the number of recurrences of cuta-
neous lesions after neonatal HSV disease, as has 
been suggested previously.15 Since skin lesions 
occur in approximately 70% of all babies with 
neonatal HSV,1 the positive socioeconomic effect 
of decreased recurrences should not be underes-
timated. For example, prevention of skin recur-
rences can translate to the need for fewer medical 
evaluations and to more days of child care atten-
Table 3. Maximum Change in Absolute Neutrophil Count during Receipt of Antiviral Suppressive Therapy.*









no. of infants/total no. (%)
Worsening by ≥2 grades 5/22 (23) 3/18 (17) 2/13 (15) 0/13
Worsening by 1 grade 3/22 (14) 2/18 (11) 2/13 (15) 5/13 (38)
No change 13/22 (59) 13/18 (72) 4/13 (31) 6/13 (46)
Improvement by ≥1 grade 1/22 (5) 0/18 5/13 (38) 2/13 (15)
* Grading was performed with the use of the World Health Organization Toxicity Grading Scale.13 The absolute neutro-
phil count was not measured in some of the infants. P=0.94 and P=0.24 for the comparison of acyclovir with placebo in 
the CASG 103 study and the CASG 104 study, respectively.
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dance, which in turn results in fewer days of work 
missed by the parent.
Previous uncontrolled studies have suggested 
that acyclovir therapy may be associated with neu-
tropenia.2,15,20-24 In the current placebo-controlled 
studies, neutropenia was not more likely to develop 
in infants receiving acyclovir than in infants re-
ceiving placebo, although the P values approached 
significance. It is possible that there is indeed an 
association that our studies were underpowered to 
detect; thus, we believe that neutropenia should 
continue to be considered as a possible toxic ef-
fect of longer-term oral acyclovir therapy.15
These data support the use of suppressive 
therapy with 300 mg of oral acyclovir per square 
meter per dose administered three times daily for 
6 months after initial treatment of neonatal HSV 
disease. Babies with skin, eye, and mouth disease 
can benefit because this therapy helps to prevent 
skin recurrences, whereas babies with CNS dis-
ease may have additional benefit with respect to 
neurodevelopmental outcomes. There are no con-
trolled data that suggest that suppressive therapy 
administered longer than 6 months or with the 
use of higher doses of oral acyclovir is beneficial. 
An extemporaneously compounded oral solution 
of valacyclovir has not been sufficiently studied in 
neonates and young infants to warrant its use in-
stead of oral acyclovir for antiviral suppression.25
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